GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cryomass Technologies Inc (OTCPK:CRYM) » Definitions » EV-to-EBIT

Cryomass Technologies (Cryomass Technologies) EV-to-EBIT : -0.74 (As of May. 15, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Cryomass Technologies EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cryomass Technologies's Enterprise Value is $10.84 Mil. Cryomass Technologies's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-14.75 Mil. Therefore, Cryomass Technologies's EV-to-EBIT for today is -0.74.

The historical rank and industry rank for Cryomass Technologies's EV-to-EBIT or its related term are showing as below:

CRYM' s EV-to-EBIT Range Over the Past 10 Years
Min: -2384.09   Med: -13.83   Max: -0.63
Current: -0.74

During the past 12 years, the highest EV-to-EBIT of Cryomass Technologies was -0.63. The lowest was -2384.09. And the median was -13.83.

CRYM's EV-to-EBIT is ranked worse than
100% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.74 vs CRYM: -0.74

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cryomass Technologies's Enterprise Value for the quarter that ended in Sep. 2023 was $22.12 Mil. Cryomass Technologies's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-14.75 Mil. Cryomass Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -66.66%.


Cryomass Technologies EV-to-EBIT Historical Data

The historical data trend for Cryomass Technologies's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryomass Technologies EV-to-EBIT Chart

Cryomass Technologies Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.54 -19.35 -2.93 -5.99 -3.64

Cryomass Technologies Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.62 -3.64 -3.09 -2.12 -1.50

Competitive Comparison of Cryomass Technologies's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Cryomass Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryomass Technologies's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cryomass Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cryomass Technologies's EV-to-EBIT falls into.



Cryomass Technologies EV-to-EBIT Calculation

Cryomass Technologies's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=10.842/-14.746
=-0.74

Cryomass Technologies's current Enterprise Value is $10.84 Mil.
Cryomass Technologies's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cryomass Technologies  (OTCPK:CRYM) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Cryomass Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 ) =EBIT / Enterprise Value (Q: Sep. 2023 )
=-14.746/22.1209664
=-66.66 %

Cryomass Technologies's Enterprise Value for the quarter that ended in Sep. 2023 was $22.12 Mil.
Cryomass Technologies's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cryomass Technologies EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Cryomass Technologies's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Cryomass Technologies (Cryomass Technologies) Business Description

Traded in Other Exchanges
N/A
Address
1001 Bannock Street, Suite 612, Denver, CO, USA, 80204
Cryomass Technologies Inc designs, manufactures, and licenses field-mobile equipment for the handling of harvested cannabis, hemp, and other high-value plant material. The company owns patented technology that utilizes liquid nitrogen to fully separate, collect and protect the high-value compounds from the harvested plant. The company's offerings include refinement systems and monitoring and control systems.
Executives
Philip Blair Mullin officer: Chief Financial Officer 3531 SOUTH LOGAN STREET, SUITE D-357, ENGLEWOOD CO 80113
Christian Noel director, officer: Chief Executive Officer 3531 SOUTH LOGAN ST. SUITE D-357, ENGLEWOOD CO 80113
Patricia Izabel Kovacevic officer: GC, Corp Secy, and Head of EA 3531 SOUTH LOGAN STREET, SUITE D-357, ENGLEWOOD CO 80113
Delon Hannes Human director 3531 SOUTH LOGAN STREET, SUITE D-357, ENGLEWOOD CO 80113
Mark Radke director 3531 SOUTH LOGAN STREET, SUITE D-357, ENGLEWOOD CO 80113
Mario Gobbo director 3531 SOUTH LOGAN STREET, SUITE D-357, ENGLEWOOD CO 80113